Shots:

• Adagene to receive upfront- development & commercial milestones- research funding and royalties on sales with certain commercialization rights for Greater China.  ADC Therapeutics to utilize Adagene’s SAFEbody technology generating Abs that will further combine with its pyrrolobenzodiazepine (PBD) cytotoxic payload technology to develop masked ADCs for solid tumors
• ADC Therapeutics also has an option to utilize SAFEbody technology for one additional exclusive target. The programs will focus on the targets in which healthy tissue expression prevent the development of ADCs
• SAFEbody technology produces masked ADCs that binds with an antigen in tumor tissues only enhancing the specificity of an ADC with minimization in off-target toxicity on healthy cells

Ref: ADC Therapeutics | Image: ADCReview